BLUEPRINT MEDICINES CORPORATION

Blueprint Medicines Corporation specializes in the manufacturing of pharmaceutical preparations, with a focused expertise in developing and producing advanced therapeutics for hematological and oncological indications. Their technical capabilities encompass the end-to-end production of precision medicines, including active pharmaceutical ingredient synthesis, formulation development, and quality-controlled manufacturing processes aligned with cGMP standards. The company demonstrates deep specialization in targeted kinase inhibitors and small-molecule drug products, emphasizing molecular design, clinical-scale manufacturing, and regulatory-compliant supply chain execution for complex therapeutics. Their differentiation lies in translating novel drug candidates into scalable, high-purity pharmaceutical formulations suitable for institutional and specialty pharmacy distribution. The organization has delivered pharmaceutical products under contract to the Department of Veterans Affairs, primarily supporting the procurement of specialized drugs for hematologic conditions and related therapies within VA’s Federal Supply Schedule framework. This engagement reflects a trusted supplier relationship focused on ensuring reliable access to critical oncology and hematology medications for veteran patients. Their primary industry focus is in NAICS 325412—pharmaceutical preparation manufacturing—where they operate as a niche developer and producer of targeted cancer therapies. The company positions itself within the precision medicine market, emphasizing small-molecule drug innovation and manufacturing for specialized clinical indications, particularly in hematologic malignancies and rare disease populations. Blueprint Medicines Corporation is structured as a 2L entity headquartered in Cambridge, Massachusetts, with operations centered on pharmaceutical R&D and manufacturing. While no government certifications are currently listed, their compliance with FDA regulations and cGMP standards underpins their eligibility for federal pharmaceutical procurement. The company maintains a concentrated presence in the U.S. biopharmaceutical corridor, serving federal healthcare systems through specialized drug supply channels.